This study significantly enhances the tumor specificity and safety of HER2-targeted radiotherapy by optimizing pretargeting strategies, providing a reproducible experimental paradigm for the development of radiopharmaceuticals.
Literature Overview
The article titled 'Preclinical evaluation of a novel tetrazine probe within a pretargeted delivery system for theranostics in HER2-positive tumor-bearing mice models,' published in Acta Pharmaceutica Sinica. B, systematically investigates the theranostic potential of a bioorthogonal click chemistry-based pretargeting system in HER2-positive tumor models. The research team designed and validated a novel radioiodinated small-molecule tetrazine probe [[131I]I-Tyr-D-peptide-PEG11-Tz], combined with trans-cyclooctene-modified pertuzumab (TCO-Per), achieving high-contrast imaging and efficient tumor killing. This strategy effectively circumvents the radiation exposure issues associated with traditional direct antibody labeling, offering new insights for the field of nuclear medicine.Background Knowledge
Currently, HER2 is highly expressed in various solid tumors and represents a key therapeutic target, including in breast, gastric, and ovarian cancers. Although targeted therapies such as trastuzumab and antibody-drug conjugates (ADCs) are available, drug resistance and toxicity remain clinical challenges. In nuclear medicine, while radioimmunotherapy (RIT) holds promise, traditional approaches involving radiolabeled antibodies suffer from slow clearance, leading to high radiation doses in organs such as bone marrow and liver, thus limiting broad clinical application. Therefore, developing safer and more efficient delivery systems is a critical bottleneck. This study leverages the inverse electron-demand Diels-Alder (IEDDA) reaction from bioorthogonal chemistry, employing a pretargeting strategy: first administering a non-radioactive TCO-antibody conjugate, allowing time for tumor accumulation and background clearance, followed by a small-molecule radioactive Tz probe that rapidly undergoes click reaction and is cleared. This design directly addresses the pharmacokinetic challenges of current HER2 radiotherapy, offering a new pathway toward highly selective and low-toxicity theranostics.
Research Methods and Experiments
The study utilized two human tumor cell lines—SKOV3 (high HER2 expression) and MGC-803 (low HER2 expression)—to establish xenograft mouse models, with HER2 expression differences confirmed via Western blot, immunohistochemistry, and flow cytometry. To identify the optimal targeting molecule, the team compared PET imaging performance of full-length pertuzumab (Per), Fab, and F(ab’)₂ fragments labeled with 89Zr, finding that Per exhibited the highest tumor uptake at 48 hours with favorable background clearance, thus selecting TCO-Per as the pretargeting agent. Subsequently, the team synthesized a novel small-molecule probe [[131I]I-Tyr-D-peptide-PEG11-Tz], which incorporates a tetrazine (Tz) reactive group, hydrophilic PEG, and D-amino acid peptide for enhanced stability, along with a tyrosine residue for radioiodination. The probe demonstrated excellent in vitro and in vivo stability, with a logD value of -2.158, indicating high hydrophilicity conducive to rapid renal excretion.
To validate the click efficiency of the pretargeting system, the team confirmed efficient in vivo coupling between TCO-Per and [[131I]I-Tyr-D-peptide-PEG11-Tz] using SEC-HPLC and in vivo serum separation assays. SPECT/CT imaging revealed sustained high tumor uptake between 48–120 hours post-injection of the probe (given 48 hours after TCO-Per), while signals in other tissues declined rapidly, achieving a maximum tumor-to-muscle ratio of 11.92. Control groups (TCO-IgG or MGC-803 models) showed no significant tumor accumulation, confirming system specificity.Key Conclusions and Perspectives
Research Significance and Prospects
This study presents a novel paradigm for precision theranostics in HER2-positive tumors. Compared to conventional radioimmunotherapy, the pretargeting system separates targeting from radiation delivery, greatly optimizing pharmacokinetics and potentially overcoming dose-limiting toxicities such as myelosuppression, thereby improving the therapeutic index. This approach is particularly suitable for α- or β-emitter therapies, minimizing damage to surrounding healthy tissues.
From a drug development perspective, this platform offers modular advantages: the same pretargeting antibody can be paired with different radiolabeled probes, enabling integrated diagnostics (e.g., 68Ga- or 18F-labeled Tz) and therapy (e.g., 131I or 177Lu). Moreover, the D-amino acid design of the probe enhances resistance to enzymatic degradation, prolonging its in vivo half-life and offering guidance for future optimization of small-molecule probes.
In disease modeling and preclinical evaluation, this system can be used to assess the targetability of novel antigens, enabling dynamic monitoring of drug distribution via PET/SPECT imaging. Future studies could extend this approach to other tumor antigens, such as TROP2 or EGFR, to build a universal pretargeting theranostic platform. Additionally, exploring faster bioorthogonal reaction pairs (e.g., TCO-tetrazine variants) could further shorten treatment cycles and improve patient compliance.
Conclusion
This study successfully developed and validated a bioorthogonal click chemistry-based HER2-targeted pretargeting theranostic system that separates targeting from radiation delivery, effectively addressing the issues of high background radiation and organ toxicity associated with conventional radioimmunotherapy. The novel probe [[131I]I-Tyr-D-peptide-PEG11-Tz] demonstrates excellent stability, rapid clearance, and high tumor specificity, significantly improving tumor-to-background ratios and enabling effective treatment with enhanced safety. This strategy not only provides a new therapeutic option for patients with HER2-positive tumors but also establishes a scalable, modular platform applicable to multiple targets and radionuclides, advancing precision nuclear medicine from concept to clinical practice. In the future, this system is expected to play a key role in early diagnosis, eradication of micrometastases, and combination immunotherapy, becoming an essential tool in comprehensive cancer management—particularly offering new hope for patients with resistance to conventional therapies. By optimizing pharmacokinetics and targeting efficiency, this study lays a solid foundation for next-generation targeted radiotherapy, marking a critical step toward personalized, low-toxicity, and highly effective cancer treatment.
